International Journal of Pharmaceutics最新文献

{"title":"A simplified method to interpret the mechanism of drug release from thin polymeric films by drug diffusivity measurements","authors":"Karin Korelc ,&nbsp;Martina M. Tzanova ,&nbsp;Anette Larsson ,&nbsp;Mario Grassi ,&nbsp;Massimiliano Pio Di Cagno ,&nbsp;Ingunn Tho","doi":"10.1016/j.ijpharm.2025.125491","DOIUrl":"10.1016/j.ijpharm.2025.125491","url":null,"abstract":"<div><div>Drug-polymer interactions and their respective affinities provide vital information for developing any polymer-containing drug delivery system, such as oral films. This paper offers a simplified method to estimate the effects of interactions between the drug and polymers in corresponding film formulations using a recently developed Fickian diffusion-based methodology. Poly(vinyl alcohol-co-vinyl acetate) (PVA/PVAc) copolymers were used as film matrix formers. To systematically vary the hydrophilicity of the polymer and drug, PVA/PVAc copolymers (monomer ratios 35:65, 50:50, 74:26, 88:12, 98:2) and model drugs, hydrochlorothiazide and caffeine (with a factor 1:30 in solubility) were used. Drug diffusivities determined in a polymer solution (5 % w/v) were compared to classical in vitro drug release from the films. The drug release rate from films containing copolymers with a lower VA/VAc ratio (35:65, 50:50, and 74:26) was significantly different for the two drugs in the first 30 min. It was found that this diffusivity method provided valuable guidance in assessing drug-polymer affinity, described as the average theoretical partition constant K_m/w between the polymer solution and pure aqueous media. This partition constant could be correlated to the drug release rate and serve as a simple, easy, and inexpensive screening method to provide deeper mechanistic insight into drug release mechanisms. This would allow enhanced sustainability and accelerate the formulation development process by reducing resources needed for the development of film formulations.</div></div>","PeriodicalId":14187,"journal":{"name":"International Journal of Pharmaceutics","volume":"675 ","pages":"Article 125491"},"PeriodicalIF":5.3,"publicationDate":"2025-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143742866","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patient in-use, room temperature and accelerated conditions stability evaluation of FDA approved clopidogrel hydrogen sulfate products","authors":"Bhanu P. Dongala,&nbsp;Rizwan Shaikh,&nbsp;Swaroop J. Pansare,&nbsp;Sunil K. Thota,&nbsp;Ziyaur Rahman,&nbsp;Mansoor A. Khan","doi":"10.1016/j.ijpharm.2025.125519","DOIUrl":"10.1016/j.ijpharm.2025.125519","url":null,"abstract":"<div><div>The objective of the study was to evaluate patient in-use, room temperature, and accelerated conditions stability of FDA-approved products of clopidogrel hydrogen sulfate (CHS). Four products (A, B, C and D) were stored at 25 °C/60 % RH (room temperature), 30 °C/75 % RH (patient in-use) and 40 °C/75 % RH (accelerated) stability conditions for 12 weeks. The products were characterized for physicochemical properties such as hardness, disintegration, assay, impurities, dissolution, Fourier-transformed infrared (FTIR), near-infrared (NIR), hyperspectral imaging, and X-ray powder diffraction (XRPD). Absorption spectroscopic and diffractometry data indicated polymorphic forms present in the products were not identical. Products A and D contained form Ⅱ, while Products B and C contained form Ⅰ of the drug. No form Ⅰ to form Ⅱ and vice-versa transformation was observed in products after exposure to stability conditions. However, an increase in crystallinity was observed with storage conditions especially at 40 °C/75 % RH. Impurity C and dissolution met pharmacopeial specifications. Dissolved drug varied from 95.2 to 97.1 % in 30 min and impurity C content was 0.04–0.57 %. After storage at various conditions, impurity C content increased insignificantly, still met pharmacopeial specification. However, Products stored at 30 °C/75 % RH (patient in-use) and 40 °C/75 % RH failed to meet dissolution specification of 85 % in 30 min due to an increase in crystallinity. In conclusion, FDA approved products of CHS contained different polymorphic forms, and crystallinity may increase on exposure to patient in-use condition which may impact clinical outcomes.</div></div>","PeriodicalId":14187,"journal":{"name":"International Journal of Pharmaceutics","volume":"675 ","pages":"Article 125519"},"PeriodicalIF":5.3,"publicationDate":"2025-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143742854","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Model-Supported dissolution methods for Modified-Release Products: Enteric-coated versus extended-release ketoprofen tablets","authors":"Mauricio A. García ,&nbsp;Jozef Al-Gousous ,&nbsp;Pablo M. González ,&nbsp;Peter Langguth","doi":"10.1016/j.ijpharm.2025.125524","DOIUrl":"10.1016/j.ijpharm.2025.125524","url":null,"abstract":"<div><div>Drug product development is often a challenging endeavor. However, model-supported dissolution test design trained by appropriate <em>in silico</em> models can lead to considerable reduction in the risk<!--> <!-->of<!--> <!-->failure. Dissolution models have revealed that dissolution of poorly soluble ionizable pharmaceutical particles is slower in biorelevant bicarbonate than compendial buffers. The reason is bicarbonate’s lowered effective pK_a (pk_a,eff), as a consequence of comparable reaction and diffusional times during dissolution. This is not necessarily the case when the drug is formulated as a controlled-release dosage form. In this paper, we explored the differences in dissolution between enteric coated (EC) and extended release (XR) ketoprofen formulations. <em>In vitro</em> dissolution was studied in low molarity buffers to mimic the lowered intestinal bicarbonate pk_a,eff, while their biorelevance was confirmed through <em>in vivo</em> comparative bioavailability studies. Both dissolution in low molarity phosphate and <em>in vivo</em> absorption profiles of EC tablets were sensitive to their coating polymer material. Similarly, XR <em>in vitro</em> dissolution in low molarity media showed discrepancies between formulations, caused by dibasic calcium phosphate in one formulation. Conversely, those <em>in vitro</em> differences were not relevant after the <em>in vivo</em> testing. Mechanistic insights from mass/charge balance modelling suggested that slower diffusional times and small liquid-to-solid ratio in XR dosage forms allow bicarbonate reactions to reach their equilibrium. This results in an enhanced buffer capacity, which was not matched by <em>in vitro</em> low molarity media. Therefore, improvement in biopredictivity of XR dosage forms can be achieved by performing dissolution experiments at high rather than low buffer molarities.</div></div>","PeriodicalId":14187,"journal":{"name":"International Journal of Pharmaceutics","volume":"675 ","pages":"Article 125524"},"PeriodicalIF":5.3,"publicationDate":"2025-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143739458","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"BMSCs laden gelatin methacrylate (GelMA) hydrogel integrating silk fibroin/hydroxyapatite scaffold with multi-layered-oriented pores for enhanced bone regeneration","authors":"Lu Wang ,&nbsp;Jie Kang ,&nbsp;Yuanjiao Li ,&nbsp;Yijing Xia ,&nbsp;Xiujuan Li ,&nbsp;Xin Du ,&nbsp;Ziruo Yin ,&nbsp;Feng Tian ,&nbsp;Feng Wu ,&nbsp;Bin Zhao","doi":"10.1016/j.ijpharm.2025.125495","DOIUrl":"10.1016/j.ijpharm.2025.125495","url":null,"abstract":"<div><div>Due to the limited regenerative ability of bone tissue, bone injury repair has always been a complicated problem in clinical treatment. Bone tissue engineering based on cell delivery is an effective method to repair bone defects, but it also puts forward strict requirements on the scaffold used in the repair process and the survival rate of cell inoculation. To address this challenge, we constructed a bone mesenchymal stem cells (BMSCs) laden gelatin methacrylate (GelMA) hydrogel to integrate in silk fibroin (SF) /nano-hydroxyapatite (nHAp) scaffold, building a dual architecture to achieve enhanced angiogenesis and bone regeneration. The GelMA hydrogel prepared by visible photo-crosslinking showed good cell loading capacity, and the multi-layered-oriented pores of the scaffold provided a suitable microenvironment for cell proliferation and nutrient exchange. We further explored the effects of this “dual-system” complex on BMSCs and in a critical-sized rat cranial defect model. The results showed that BMSCs@GelMA-SF/nHAp composite scaffold with directional pore structure was more conducive to the repair of skull defects in rats due to the faster rate of vascularization and osteogenesis, indicating the developed gel-scaffold complex would be a promising therapeutic strategy for the repair of bone defects regeneration.</div></div>","PeriodicalId":14187,"journal":{"name":"International Journal of Pharmaceutics","volume":"675 ","pages":"Article 125495"},"PeriodicalIF":5.3,"publicationDate":"2025-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143742870","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Generation of continuous production of polymeric nanoparticles via microfluidics for aerosolised localised drug delivery","authors":"Giuseppina Catania ,&nbsp;Giulia Guerriero ,&nbsp;Naoual Bakrin ,&nbsp;Jérémie Pourchez ,&nbsp;Ghalia Kaouane ,&nbsp;Lara Leclerc ,&nbsp;Lionel Augeul ,&nbsp;Ragna Haegebaert ,&nbsp;Katrien Remaut ,&nbsp;David Kryza ,&nbsp;Giovanna Lollo","doi":"10.1016/j.ijpharm.2025.125532","DOIUrl":"10.1016/j.ijpharm.2025.125532","url":null,"abstract":"<div><div>Transferring the production of nanoparticles from laboratory batches to large-scale production for preclinical and clinical applications represents a challenge due to difficulties in scaling up formulations and lack of suitable preclinical models for testing. Here, we transpose the production of hyaluronic acid and polyarginine-based nanoparticles encapsulating the platinum-derivative dichloro(1,2 diaminocyclohexane)platinum(II), from conventional bulk method to continuous production using microfluidics. The microfluidic-based drug delivery system is then tested in a customised preclinical setup to assess its suitability for pressurised intraperitoneal aerosol chemotherapy (PIPAC), a locoregional chemotherapy used to treat peritoneal carcinomatosis. PIPAC consists of the aerosolization of drugs under pressure using laparoscopy. In our preclinical setup, two clinical aerosol devices, CapnoPen® and TOPOL®, are used in conjunction with syringe pump to achieve the clinically optimal aerosol droplet size range (25–50 μm). Aerosol droplet sizes of 38 and 64 μm are obtained at upstream pressures of 14.7 and 7.4 bar and flow rates of 0.4 and 1.1 mL/s, for CapnoPen® and TOPOL®, respectively. To study the spatial distribution of the aerosol, our preclinical setup is then coupled to an <em>ex-vivo</em> model (inverted porcine urinary bladder) that mimics the physiological peritoneal cavity environment. The smaller droplet size obtained with CapnoPen® provided more homogeneous aerosol distribution in the bladder cavity, crucial for maximising treatment coverage within the peritoneal cavity. Furthermore, stability studies reveal that nanoparticles maintained their physicochemical properties and anticancer activity post-aerosolization. Overall, this study provides a scalable approach for the production of platinum-derivative-loaded polymeric nanoparticles and demonstrates the suitability of this DDS for PIPAC.</div></div>","PeriodicalId":14187,"journal":{"name":"International Journal of Pharmaceutics","volume":"675 ","pages":"Article 125532"},"PeriodicalIF":5.3,"publicationDate":"2025-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143742889","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development of nanovehicles for co-delivery of colistin and ArnT inhibitors","authors":"Valentina Pastore ,&nbsp;Jessica Frison ,&nbsp;Cristiano Pesce ,&nbsp;Mariya Ryzhuk ,&nbsp;Mariangela Garofalo ,&nbsp;Martina Cristoferi ,&nbsp;Silvia Cammarone ,&nbsp;Giorgia Fabrizio ,&nbsp;Maria Carmela Bonaccorsi Di Patti ,&nbsp;Deborah Quaglio ,&nbsp;Francesca Ghirga ,&nbsp;Francesco Imperi ,&nbsp;Mattia Mori ,&nbsp;Paolo Caliceti ,&nbsp;Bruno Botta ,&nbsp;Fiorentina Ascenzioni ,&nbsp;Stefano Salmaso","doi":"10.1016/j.ijpharm.2025.125515","DOIUrl":"10.1016/j.ijpharm.2025.125515","url":null,"abstract":"<div><div>Antimicrobial resistance (AMR) represents a critical global health challenge, with increasing prevalence among high-priority pathogens such as <em>Pseudomonas aeruginosa</em>. Colistin, a last-resort antibiotic, faces limitations in efficacy due to toxicity and bacterial resistance, primarily driven by lipid A modifications that impair colistin binding. In <em>P. aeruginosa</em>, resistance to colistin is mainly due to activation of the <em>arn</em> operon whose last enzyme is ArnT. This study explores a liposomal nanocarrier approach to co-deliver colistin with an ArnT inhibitor, isostevic acid (ISA), aiming to restore colistin’s efficacy against resistant <em>P. aeruginosa</em> strain. We designed liposomes incorporating colistin in the aqueous core and ISA within the lipid bilayer, optimizing formulations to achieve stable, high-efficiency encapsulation by varying the cholesterol/egg phosphatidylcholine ratios. These co-loaded liposomes demonstrated enhanced antimicrobial activity, significantly lowering the minimum inhibitory concentration (MIC) of colistin against resistant strain. The dual-drug liposomes also achieved bactericidal effects at lower colistin concentrations compared to the free drug, attributed to the synergistic action of ISA as an adjuvant that locks colistin resistance mechanisms. The results suggest that liposome-mediated co-delivery of colistin and ISA offers a promising strategy to counteract colistin-resistant infections. This approach could improve the clinical management of multidrug-resistant <em>P. aeruginosa</em> and highlights the potential for liposomal systems to modulate drug release and target bacterial resistance mechanisms.</div></div>","PeriodicalId":14187,"journal":{"name":"International Journal of Pharmaceutics","volume":"675 ","pages":"Article 125515"},"PeriodicalIF":5.3,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143730150","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advance of the application of seaweed polysaccharides on antitumor drug delivery systems","authors":"Xiaofei Yin ,&nbsp;Xinrong Geng ,&nbsp;Wenjun Li ,&nbsp;Tuanjie Che ,&nbsp;Libo Yan ,&nbsp;Biao Yuan ,&nbsp;Song Qin","doi":"10.1016/j.ijpharm.2025.125502","DOIUrl":"10.1016/j.ijpharm.2025.125502","url":null,"abstract":"<div><div>In recent years, the morbidity and death rate of patients with tumors have been continuously increasing. How to administer radiotherapy, chemotherapy, and other methods for reducing damage to normal tissue cells and accurately targeting the tumor is one of the key issues in solving the problem of cancer. Using nanocarriers is a feasible approach into targeted control on the release of medicine to increase patient compliance. Nowadays, many researchers are gradually focusing on the application of drug delivery systems with natural ingredients as carriers in tumor therapy. At the same time, natural active ingredients may have better biocompatibility and fewer side effects. Especially, a variety of polysaccharides from seaweeds has exhibited antitumor activity, providing greater possibilities for their use as drug delivery carriers. To facilitate the advancement and clinical translation of seaweed-derived polysaccharides in medical applications, we summarized the structural features of a range of polysaccharides extracted from macroalgae, their physical properties suitable for use as carriers, and the ways they are utilized in delivering medicines in oncology therapy (particularly in combination with novel oncology therapies, such as immunotherapy and photothermal therapy).</div></div>","PeriodicalId":14187,"journal":{"name":"International Journal of Pharmaceutics","volume":"675 ","pages":"Article 125502"},"PeriodicalIF":5.3,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143730148","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Amoxicillin-loaded polycaprolactone-gelatin nanofiber/net (NFN) matrices for pneumothorax treatment","authors":"Gökçe Mülazımoğlu ,&nbsp;Ülkü Çayır ,&nbsp;Demet Çakır ,&nbsp;Menemşe Gümüşderelioğlu","doi":"10.1016/j.ijpharm.2025.125525","DOIUrl":"10.1016/j.ijpharm.2025.125525","url":null,"abstract":"<div><div>The recurrence rate of spontaneous pneumothorax (collapsed lung) is 30 % after basic conservative treatments, and it can reach up to 20 % after surgery due to the limited effectiveness of current surgical techniques. This highlights the need for the development of new, effective treatment approaches supported by biomaterials. Therefore, we aimed to develop a biomaterial that does not restrict the aerodynamic movements of the lungs, is resistant to lung pressure, and can withstand the movements during inhalation and exhalation,to prevent and treat pneumothorax recurrence. For this purpose, biodegradable matrices were prepared using polycaprolactone (PCL), gelatin (GEL), and amoxicillin (AMX), which is a broad-spectrum antibiotic. The matrices were designed with a nanofiber/net (NFN) structure, targeting appropriate degradation rates and mechanical strength. NFN matrices with randomly arranged and bead-free fibers were produced by electrospinning PCL/GEL and PCL/GEL-AMX solutions in different ratios. The incorporation of AMX reduced the fiber diameter, while the addition of GEL increased the fiber diameters, resulting in fibrous matrices with diameters ranging from 194 nm to 1,100 nm. Additionally, adding GEL and/or AMX to the structure caused the fiber surfaces to resemble tree bark, and spider web-like nano networks formed between the fibers. These formations were particularly homogeneous and dense in the (7:3) PCL/GEL-5AMX group. Energy dispersive X-ray (EDX) analysis showed that the elemental composition of the fibers and the nano-networks was similar. The elastic moduli of the matrix groups ranged from 3.97 ± 0.74 MPa to 19.02 ± 1.91 MPa, which was found to be suitable for the target range for lung tissue. Hydrolytic degradation studies indicated that nano-networks remained present in the structure after 5 weeks, and 55–68 % of the loaded AMX was released within 14 days. In the AMX-loaded groups, both <em>Escherichia coli</em> (<em>E. coli</em>) and <em>Streptococcus aureus</em> (<em>S. aureus</em>) growth were inhibited, with the most effective inhibition observed in the (7:3) PCL/GEL-5AMX group. In conclusion, it was assessed that the spider web-like nano-networks, which increased with the GEL and AMX ratio in the solution, mimicked the structure of lung alveoli at the nanoscale due to their large surface area and small pore size between the fibers. Particularly, the (7:3) PCL/GEL-5AMX NFN matrix could be used as a new and effective alternative material in pneumothorax therapy.</div></div>","PeriodicalId":14187,"journal":{"name":"International Journal of Pharmaceutics","volume":"675 ","pages":"Article 125525"},"PeriodicalIF":5.3,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143725529","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Process development of tangential flow filtration and sterile filtration for manufacturing of mRNA-lipid nanoparticles: A study on membrane performance and filtration modeling","authors":"Wenjun Wu,&nbsp;Liliam Teixeira Oliveira,&nbsp;Aarushi Jain,&nbsp;Yury Karpov,&nbsp;Kirstin Olsen,&nbsp;Yu Wu,&nbsp;Rajesh Krishnan Gopalakrishna Panicker","doi":"10.1016/j.ijpharm.2025.125520","DOIUrl":"10.1016/j.ijpharm.2025.125520","url":null,"abstract":"<div><div>Lipid nanoparticles (LNPs) are the most studied delivery systems for mRNA therapeutics and have gained importance in both industry and academia following the approval of multiple mRNA-LNP-based vaccines since 2021. The COVID-19 pandemic proved the remarkable efficacy and rapid deployment of mRNA-LNP vaccines, reinforcing their potential for broader therapeutic and vaccine applications. Currently, multiple mRNA-LNPs are in various stages of preclinical and clinical development. LNPs are sensitive to the manufacturing process, and to mitigate the risks associated with bringing an mRNA-LNP from benchtop to industrial scale, it is recommended to have a systematic process development approach, including mathematical modeling and statistical analysis. Among the unit operations required for mRNA-LNP manufacturing, concentration and buffer exchange by tangential flow filtration (TFF), as well as sterile filtration, are challenging and must be optimized to guarantee process scalability and product quality, while avoiding issues such as membrane fouling and incorrect filter capacity. This study investigates the optimization of TFF and sterile filtration parameters to manufacture higher concentration mRNA-LNPs necessary for cancer vaccines, particularly personalized cancer vaccines. Various flat-sheet TFF cartridges were tested under different process parameters, including flow rate and transmembrane pressure (TMP), to identify the most effective process conditions. Furthermore, the sterile filtration of mRNA-LNPs was analyzed using the gradual plugging model, providing insights into improving filter capacity, optimizing filtration pressures, and defining the design space for large-scale manufacturing. These findings contribute to the development of a robust and scalable mRNA-LNP manufacturing process ensuring product quality.</div></div>","PeriodicalId":14187,"journal":{"name":"International Journal of Pharmaceutics","volume":"675 ","pages":"Article 125520"},"PeriodicalIF":5.3,"publicationDate":"2025-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143725400","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"NIR laser-activated, indocyanine green-loaded bovine serum albumin nanoparticles: An established ingestible photosensitizer for a novel approach to controlling vector-borne organisms","authors":"Kexin Zhang ,&nbsp;Chenfei Zhang ,&nbsp;Ying Li ,&nbsp;Ting Li ,&nbsp;Yansong Yin ,&nbsp;Kaipeng Wang ,&nbsp;Anqi Wang ,&nbsp;Mingjia Zheng ,&nbsp;Zhong Zhang ,&nbsp;Haijun Wang","doi":"10.1016/j.ijpharm.2025.125517","DOIUrl":"10.1016/j.ijpharm.2025.125517","url":null,"abstract":"<div><div>In this study, we proposed a novel application of an established material by developing ingestible nanoparticles made from bovine serum albumin loaded with indocyanine green. These nanoparticles, referred to as ICG@BSA NPs, response to near infrared (NIR) laser exposure by generating reactive oxygen species. This process, known as photodynamic therapy (PDT), is designed to targeted kill vector-borne organisms. As a representative model of vectors, housefly larvae trended to uptake more protein-based ICG@BSA NPs than free ICG. This led neither to an obvious influence on larval development nor to a significant impact on the intestinal microbial population. In contrast, under NIR laser irradiation, ICG@BSA NPs could efficiently induce generation of ROS for killing larvae <em>via</em> damaging intestinal wall and inducing subsequent intestinal bacteria leakage. This protein-based ingestible nanoparticles integrate the independence of pesticides, pronounced PDT efficacy, and environmental friendliness, making this nanoplatform promising for controlling vector-borne organisms and associated diseases.</div></div>","PeriodicalId":14187,"journal":{"name":"International Journal of Pharmaceutics","volume":"675 ","pages":"Article 125517"},"PeriodicalIF":5.3,"publicationDate":"2025-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143730157","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}